Theranos

By 2014, Theranos was valued at roughly nine billion dollars, and its founder, Elizabeth Holmes, was on magazine covers as the youngest self-made female billionaire in the world. The company's claim was extraordinary: a single drop of blood, pricked from a fingertip, run through a proprietary device called the Edison, could deliver a full panel of lab tests that normally required several vials drawn from a vein.

Investors, board members — including several former US cabinet secretaries and senior military officials — and pharmacy partners like Walgreens all bought into the vision, in some cases without independent verification of whether the technology actually worked as claimed.

It didn't. Internally, the Edison device could reliably run only a small fraction of the tests Theranos publicly claimed it could perform. For the rest, the company was reportedly running samples on standard, off-the-shelf lab equipment from other manufacturers — the exact machines Theranos claimed to be making obsolete — while telling investors, regulators, and patients that its own proprietary technology was doing the work.

Investigative reporting, beginning with the Wall Street Journal in 2015, unraveled the gap between the claims and the reality. Theranos dissolved in 2018. Holmes was later convicted of fraud.

What makes Theranos more than just another failed startup is the board. It wasn't a company that fooled no one with any power to ask hard questions — it was surrounded by genuinely accomplished, credentialed people, and the scrutiny still failed. A board stacked with impressive names is not the same thing as a board equipped or willing to independently verify the core technical claim the entire company rested on. Prestige is not due diligence.